Novexel

Company: Novexel
Financing: $64.7 million
Website: http://www.novexel.com/

In January of 2007 Novexel landed €50 million ($64.7 million) in a second round of financing. The round was led by new investor Edmond de Rothschild Investment Partners of Paris along with Atlas Venture, Sofinnova, Abingworth, 3i, Novo A/S, BIT, Goldman Sachs, NeoMed and NIF SMBC.

Novexel is taking aim at the hot anti-infectives market that is being fueled by increasingly resistant superbugs. The company already has three antibacterials in Phase I clinical trials. An additional anti-fungal drug--NXL201--is undergoing reformulation studies after initiation of Phase I clinical trials. Novexel says that the funding will carry the company through 2009, and that it will look to in-license additional drug candidates to further bolster its pipeline.

Related Articles:
Novexel licenses anti-fungal drug. Report
New compounds combat bacteria's defenses. Report

 

Novexel
Read more on

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i